InDex Pharmaceuticals Holding AB

InDex Pharmaceuticals Holding AB (publ), a pharmaceutical development company, develops pharmaceutical products for patients with ulcerative colitis. The company's lead drug candidate is Cobitolimod, which is in phase III clinical development for the treatment of patients with moderate to severe ulcerative colitis. It also develops a portfolio of other DNA based immunomodulatory sequences in preclinical stage for the treatment of various immunological diseases. The company was founded in 2000 and is headquartered in Solna, Sweden. Show More...